{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:03:11Z","timestamp":1770220991732,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012359","name":"Promotion and Mutual Aid Corporation for Private Schools of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ijpharm.2016.10.033","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T15:02:13Z","timestamp":1476889333000},"page":"315-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Systemic delivery of small interfering RNA targeting nuclear factor \u03baB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles"],"prefix":"10.1016","volume":"515","author":[{"given":"Takanori","family":"Kanazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisako","family":"Ibaraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuuki","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Seta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.10.033_bib0005","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.18553\/jmcp.2011.17.s9-b.S14","article-title":"Biologic agents in rheumatoid arthritis: an update for managed care professionals","volume":"17","author":"Agarwal","year":"2011","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/ar2457","article-title":"The roles of the classical and alternative nuclear factorkappaB pathways: potential implications for autoimmunity and rheumatoid arthritis","volume":"10","author":"Brown","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0015","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/kem075","article-title":"Longterm infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders","volume":"46","author":"Buch","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.0105-2896.2009.00862.x","article-title":"Gene discovery in rheumatoid arthritis highlights the CD40\/NF-(B signaling pathway in disease pathogenesis","volume":"233","author":"Criswell","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","article-title":"Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis","volume":"80","author":"Dadouna","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0030","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/rheumatology\/kes417","article-title":"Small molecules targeting JAKs\u2013a new approach in the treatment of rheumatoid arthritis","volume":"52","author":"Feist","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-857X(05)70201-5","article-title":"The epidemiology of rheumatoid arthritis","volume":"27","author":"Gabriel","year":"2001","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijpharm.2011.02.060","article-title":"Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis","volume":"416","author":"Hofkens","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0045","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s11095-011-0440-7","article-title":"Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration","volume":"28","author":"Kanazawa","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0050","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","article-title":"Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles","volume":"34","author":"Kanazawa","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/pharmaceutics7030294","article-title":"Topical anti-nuclear factor-kappa B small interfering RNA with functional peptides containing sericin-based hydrogel for atopic dermatitis","volume":"7","author":"Kanazawa","year":"2015","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2015.05.003","article-title":"Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical treatment of atopic dermatitis","volume":"489","author":"Kanazawa","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0065","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1521-6942(03)00048-2","article-title":"Pharmacological treatment of established rheumatoid arthritis","volume":"17","author":"Lee","year":"2003","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0070","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/ard.2003.009944","article-title":"Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis","volume":"63","author":"Metselaar","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1773-2247(14)50001-9","article-title":"Cytoplasm-responsive delivery systems for siRNA using cell-penetrating peptide nanomicelles","volume":"24","author":"Okada","year":"2014","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0085","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2655","article-title":"Regulation of tissue homeostasis by NF-(B signalling: implications for inflammatory diseases","volume":"9","author":"Pasparakis","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0090","first-page":"2","article-title":"Aggressive treatment of early rheumatoid arthritis to prevent joint damage","volume":"47","author":"Pincus","year":"1998","journal-title":"Bull. Rheumatol. Dis."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/15360288.2014.959238","article-title":"Methotrexate: a gold standard for treatment of rheumatoid arthritis","volume":"28","author":"Shinde","year":"2014","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0100","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/rheumatology\/kem298","article-title":"Signalling, inflammation and arthritis: NF-(B and its relevance to arthritis and inflammation","volume":"47","author":"Simmonds","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0105","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for the treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbspin.2009.05.011","article-title":"New insights in synovial angiogenesis","volume":"77","author":"Szekanecz","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2010.07.038","article-title":"Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhances siRNA uptake and gene silencing","volume":"398","author":"Tanaka","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2013.07.069","article-title":"Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery","volume":"455","author":"Tanaka","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2003.10.006","article-title":"Deformable liposomes for dermal administration of methotrexate","volume":"270","author":"Trotta","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.111.180042","article-title":"Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002","volume":"338","author":"Uchida","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0135","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1172\/JCI75673","article-title":"Peptide-siRNA nanocomplexes targeting NF-\u03baB subunit p65 suppress nascent experimental arthritis","volume":"124","author":"Zhou","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar3324","article-title":"Negative regulation of NF-kappaB and its involvement in rheumatoid arthritis","volume":"13","author":"van Loo","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ijpharm.2016.10.033_bib0145","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/mp2000742","article-title":"Liposomal drug formulations in the treatment of rheumatoid arthritis","volume":"8","author":"van den Hoven","year":"2011","journal-title":"Mol. Pharm."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316309760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316309760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T19:07:01Z","timestamp":1657480021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316309760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0378517316309760"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.033","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic delivery of small interfering RNA targeting nuclear factor \u03baB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}